Skip to main content

Articles By Jack Cush, MD

muscle%20aches.jpg

Long-Term Outcomes of Aromatase Inhibitor Arthralgias

Aromatase inhibitors (AI) are often given in the setting of estrogen receptor-positive (ER+) breast cancer therapy.

Read Article
OP.risk_.jpg

Those with Osteoporotic Fractures are Going Untreated

The International Osteoporosis Foundation (IOF) reports that nearly 80% of those who have already suffered a broken bone due to osteoporosis remain unprotected against the risk of further disabling fractures.

Read Article
CAPS.criteria1.jpg

New Criteria for the Cryopyrinopathies (CAPS)

The diagnosis of periodic fevers is unified by undiagnosed but recurrent fever. Unfortunately the diagnosis of these disorders is hampered by their infrequency, protean features and a lack of clear criteria. Even more problematic is knowing who should be tested and for which monogenic marker?

Read Article
Week%20in%20Review.JPG

RheumNow Week in Review – 7 October 2016

Dr. Jack Cush reviews highlights from the journals and news this week on RheumNow.com.

Read Article
Lknee.OA_.jpg

CDC Says Prevalence of Severe Joint Pain is Rising

The October 7th edition of MMWR reports that severe joint pain (SJP) has significantly risen from 10.5 million in 2012 to 27.2% in 2014, based on recent NHIS surveys.

Read Article
biosimilars2.jpg

Biosimilar Reports – October 2016

RheumNow will periodically review this subject with “Biosimilar Reports” providing updates, news, new publications, overview articles and research results impacting to biosimilar development and use.

Read Article
glomerulonephritis.jpg

Lupus Nephritis Therapies Reviewed

Singh and colleagues have published a systematic review and Bayesian network metaanalyses of clinical trials of immunosuppressive drugs and corticosteroids in patients with lupus nephriti.

Read Article
moneyglobe.jpg

Pharma Points Blame at PBMs

A Wall Street Journal article claims that U.S. drugmakers are pointing the blame at the middlemen who also influence drug priciing.

Read Article
PSO.Palmoplantar.jpg

Anti-IL-23 Guselkumab Beats Adalimumab in Severe Psoriasis

Management of moderate to severe plaque psoriasis has advanced significantly with FDA approved therapies capable of targeting TNF alpha, IL-17 and IL-12/23.  

Read Article
nOPHyt4.jpg

BUILD Study - Baricitinib Shows Rapid Efficacy and X-ray Protection

Baricitinib is an oral, small molecule, once-daily DMARD, that specifically inhibits Janus kinase 1 and 2 and is being developed for use in rheumatoid arthritis. With much of the developmental clinical trials completed, the drug is slated for review and potential approval near the end of the year.

Read Article
×